Non-viral delivery for gene therapy

A next generation gene therapy delivery approach
The Duchenne Research Fund committed £320,000 to accelerate research into alternative ways to deliver gene therapy to Duchenne patients, with the aim of increasing the number of patients who can receive gene therapy treatments.

Several clinical trials are now under way to explore the efficacy of gene transfer, a type of gene therapy, as a treatment for Duchenne. This entails using a micro-dystrophin – a shortened form of the dystrophin gene – with the aim of producing a functional dystrophin protein that patients’ bodies can utilise.

Current investigational gene transfer candidates for Duchenne make use of an adeno-associated virus (AAV). An AAV is a virus that is not known to cause disease and that acts as the delivery vehicle to carry the micro-dystrophin to patients’ cells.

As viral based gene therapies continue to demonstrate therapeutic benefit in the clinic, DRF believes it is crucial to also invest in non-viral delivery methods. These technologies may provide strategies to complement current viral gene therapies by potentially increasing cargo size, widening patient eligibility and potentially offering methods to re-administer gene therapies to patients who have already received a viral-based therapy.

DRF has provided funding for Solid Biosciences’ non-viral delivery research programme, which has partnered with experts across three different labs, two working in nanoparticle formation to develop and optimise a nanoparticle-based gene delivery system, and one working in exosome development as a further alternative to current gene delivery mechanisms.

Pre-clinical research

£320,000 contribution

2018-2020

Cambridge, MA, USA

Latest research news

Duchenne Care UK podcast series launched

On World Duchenne Awareness Day 2026, we are pleased to share the launch of the Duchenne Care UK podcast series. The series is based on the Duchenne Care UK Patient and Family Guides and break down information into accessible, short episodes …

Landmark day for Duchenne as Givinostat approved for use in England

On a landmark day for the Duchenne muscular dystrophy community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended the treatment givinostat (brand name Duvyzat) for use on the NHS in England. In final draft...

Our projects

Learn more about what we fund.

Get involved

Find out how you can help us beat Duchenne.